Consortium brings together industry, academic, and regulatory experts to advance research and bridge gaps in drug development targeting Alzheimer’s disease Asceneuron to contribute its expertise in neurodegenerative disease to advance biomarkers for drug development in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 26 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to […]